FDA Approves Livmarli (maralixibat) for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

[unable to retrieve full-text content]FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 29, 2021– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Livmarli (maralixibat) oral solution for…
Drugs.com – New Drug Approvals